Pham P and Bartlett JG
Available formulation in Zambia: Capsule: 500 mg; 1 g (as sodium salt). Powder for injection: 500 mg (as sodium salt) vial. Powder for oral liquid: 125 mg (as sodium salt)/5 ml.
- Indicated for infections due to beta-lactamase-producing staphylococci.
- Empiric treatment for S. aureus infections: cloxacillin 2 gm IV q6h
Cellulitis and other soft tissue infections: cloxacillin 1-2 gm IV q6h
Diabetic foot ulcer: cloxacillin 2 gm IV q6h plus gentamicin and metronidazole.
Septic arthritis and osteomyelitis: cloxacillin 2 gm IV q6h
Zambia Information Author: Paul A. Pham, Pharm. D.
- No longer available in the U.S.
- Staphylococcal infections
- Skin and soft tissue infections
- Streptococcal infections
|Coxapen; Tegopen||Cloxacillin||No longer available in the U.S. ||oral |
*Prices represent cost per unit specified and are representative of "Average Wholesale Price" (AWP).
AWP Prices were obtained and gathered by Lakshmi Vasist Pharm D using the Red Book, manufacturer's
information, and the McKesson database.
^Dosage is indicated in mg unless otherwise noted.
250-500 mg po q6h.
- Hypersensitivity reactions and rash.
- GI intolerance and diarrhea
- Drug fever
- Coombs' test positive without hemolytic anemia
- Jarisch-Herxheimer reaction (with treatment of spirochetal infections)
C. difficile -associated colitis
- LFT elevation s
Tetracyclines :in vitro antagonism when co-administered. Bactericidal effect of penicillins may be diminished in vivo. Avoid co-administration.
- Hemolytic anemia
- Interstitial nephritis
No longer available in the U.S. Four times a day dosing may decrease patient adherence.